



MALIGNANT LIVER TUMORS

Current and Emerging Therapies

THIRD EDITION




R
2
3
7

Edited by
Pierre-Alain Clavien

Deputy Editor
Stefan Breitenstein

Associate Editors
Jacques Belghiti
Ravi S. Chari
Josep M. Llovet
Chung-Mau Lo
Michael A. Morse
Tadatoshi Takayama
Jean-Nicolas Vauthey



 **WILEY-BLACKWELL**

Malignant Liver Tumors

Current and Emerging Therapies

THIRD EDITION

EDITED BY

Pierre-Alain Clavien, MD, PhD, FACS, FRCS

Professor and Chairman
Department of Surgery
Swiss Hepato-Pancreato-Biliary and Transplantation Center
University Hospital Zurich
Zurich, Switzerland

DEPUTY EDITOR

Stefan Breitenstein, MD

Department of Surgery
Swiss Hepato-Pancreato-Biliary and Transplantation Center
University Hospital Zurich
Zurich, Switzerland

ASSOCIATE EDITORS

Jacques Belghiti, MD

Professor of Surgery
Department of Hepatobiliary Surgery
Hospital Beaujon
Clichy, France

Ravi S. Chari, MD, MBA

Professor of Surgery and Cancer Biology
Vanderbilt University Medical Center
Nashville, TN, USA

Josep M. Llovet, MD

Associate Professor of Medicine
Liver Cancer Program
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York, USA;
Professor of Research – ICREA
BCLC Group, IDIBAPS, Liver Unit
Hospital Clinic
Barcelona, Spain

Chung-Mau Lo, MS, FRCS (Ed), FRACS, FACS

Professor
Divisions of Hepatobiliary/Pancreatic Surgery
and Liver Transplantation
Departments of Surgery
The University of Hong Kong
Queen Mary Hospital
Hong Kong, China

Michael A. Morse, MD, MHS

Associate Professor of Medicine
Division of Medical Oncology, GI Oncology
Molecular Therapeutics Program
Duke University Medical Center
Durham, NC, USA

Tadatoshi Takayama, MD, PhD

Professor
Department of Digestive Surgery
Nihon University School of Medicine
Tokyo, Japan

Jean-Nicolas Vauthey, MD, FACS

Professor of Surgery
Liver Service
Department of Surgical Oncology
The University of Texas M.D. Anderson
Cancer Center
Houston, TX, USA

 **WILEY-BLACKWELL**

A John Wiley & Sons, Ltd., Publication

This edition first published 2010, © 2010 by Blackwell Publishing Ltd

Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell's publishing program has been merged with Wiley's global Scientific, Technical and Medical business to form Wiley-Blackwell.

Registered office: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Malignant liver tumors : current and emerging therapies / edited by Pierre-Alain Clavien ; deputy editor, Stefan Breitenstein ; associate editors, Jacques Belghiti . . . [et al.]. – 3rd ed.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-4051-7976-8

1. Liver—Cancer—Treatment. I. Clavien, Pierre-Alain.

[DNLM: 1. Liver Neoplasms—therapy. WI 735 M251 2010]

RC280.L5L578 2010

616.99'436—dc22

2009029874

ISBN: 9781405179768

A catalogue record for this book is available from the British Library.

Set in 9/12 pt Meridien by Toppan Best-set Premedia Limited

Printed and bound in Singapore by Fabulous Printers Pte Ltd

Contributors

Michael Abecassis, MD

Professor
Division of Organ Transplantation
Department of Surgery
Northwestern University
Chicago, IL, USA

Ghassan K. Abou-Alfa, MD

Department of Medicine
Division of Gastrointestinal Oncology
Memorial Sloan-Kettering Cancer Center
New York, NY, USA

Clara Alsinet, PhD

Barcelona-Clinic-Liver-Cancer (BCLC) Group,
Institut d' Investigacions Biomèdiques August Pi
i Sunyer (IDIBAPS)
Centro de Investigaciones Biomédicas en Red
(CIBEREHD)
Liver Unit, Hospital Clínic
Barcelona, Spain

Carmen Ayuso, MD

Senior Consultant
Barcelona-Clinic-Liver-Cancer (BCLC) Group
Department of Radiology
Hospital Clínic, University of Barcelona
Centro de Investigaciones Biomédicas en Red
Institut d' Investigacions Biomèdiques August Pi
i Sunyer (IDIBAPS)
Barcelona, Spain

Jacques Belghiti, MD

Professor of Surgery
Department of Hepatobiliary Surgery
Hospital Beaujon
Clichy, France

Inne H.M. Borel Rinkes, MD, PhD

Professor of Surgery
Department of Surgery
University Medical Center
Utrecht, The Netherlands

Stefan Breitenstein, MD

Department of Surgery
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Jordi Bruix, MD

Senior Consultant
Barcelona-Clinic-Liver-Cancer (BCLC) Group
Liver Unit
Hospital Clínic, University of Barcelona
Centro de Investigaciones Biomédicas en Red
Institut d' Investigacions Biomèdiques August Pi
i Sunyer (IDIBAPS)
Barcelona, Spain

Barrie R. Cassileth, MS, PhD

Integrative Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, NY, USA

A. Bapsi Chakravarthy, MD

Associate Professor
Department of Radiation Oncology
Vanderbilt University
Nashville, TN, USA

Ravi S. Chari, MD

Professor of Surgery and Cancer Biology
Vanderbilt University Medical Center
Nashville, TN, USA

Miin-Fu Chen, MD, FACS

Department of General Surgery
Chang-Gung Memorial Hospital
Chang-Gung University Medical School
Taoyuan, Taiwan

Daniel Cherqui, MD

Professor of Surgery
Chief Department of Digestive and Hepatobiliary
Surgery
Hôpital Henri Mondor – Université Paris
Créteil, France

Yun Shin Chun, MD

Department of Surgical Oncology
The University of Texas M.D. Anderson Cancer
Center
Houston, TX, USA

Pierre-Alain Clavien, MD, PhD

Professor
Department of Surgery
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Menghua Dai, MD

Department of Surgery
Memorial Sloan-Kettering Cancer Center
New York, NY, USA

Olivier de Rougemont, MD

Department of Surgery
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Eduardo de Santibañes,

MD, PhD, FACS
Professor of Surgery
Hepatobiliopancreatic and Liver Transplant Unit
Hospital Italiano
Buenos Aires, Argentina

Ruth De Bruyne, MD

Department of Pediatrics
Section of Pediatric Gastroenterology
University Medical Center Ghent
Ghent, Belgium

Dimitrios Dimitroulis, MD

Department of Surgery
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Phuong L. Doan, MD

Department of Medicine
Division of Medical Oncology
Duke University Medical Center
Durham, NC, USA

M.B. Majella Doyle, MD

Assistant Professor of Surgery
Washington University School of Medicine
Department of Surgery
Section of Liver Transplant and Hepatobiliary
Surgery
St Louis, MO, USA

François Durand, MD

Hepatology and Liver Intensive Care
Hospital Beaujon
Clichy, France

Philipp Dutkowski, MD

Department of Surgery
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Ashraf Mohammad El-Badry

MB.BCh, MCh, MD
Department of Surgery
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Christian Ernst, Prof Dr

Economics and Management of Social Services
University Hohenheim
Stuttgart, Germany

Yuman Fong, MD

Murray F. Brennan Chair in Surgery
Memorial Sloan-Kettering Cancer Center
New York, NY, USA

Claire Francoz, MD

Hepatology and Liver Intensive Care
Hospital Beaujon
Clichy, France

Sivakumar Gananadha

Senior lecturer
Department of Surgery
The Canberra Hospital
Australian National University Medical School
Canberra, Australia

Lorena Gonzalez, MD

Department of Surgery
Memorial Sloan-Kettering Cancer Center
New York, NY, USA

Jyothirmai Gubili, MS, FACS

Integrative Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, NY, USA

Thomas F. Hany, MD

Department of Nuclear Medicine
University Hospital Zurich
Zurich, Switzerland

Charles K. Heller III, DO

Surgery Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD, USA

Michael A. Heneghan, MD,

MMedSc, FRCPI
Consultant Hepatologist & Lead Clinician for
Hepatology
Institute of Liver Studies
King's College Hospital
London, UK

Juan Hepp, MD, FACS

Professor of Surgery
Clínica Alemana – Universidad del Desarrollo
School of Medicine
Department of Surgery
Clínica Alemana Santiago
Santiago, Chile

Fidel D. Huitzil-Melendez, MD

Departamento de Hematología y Oncología
Instituto Nacional de Ciencias Médicas y
Nutrición “Salvador Zubirán”
Mexico, D. F. Mexico

Zakiyah Kadry, MD, FACS

Professor of Surgery
Division of Transplantation
Department of Surgery
Penn State Milton S. Hershey Medical Center
Hershey, PA, USA

Nancy Kemeny, MD

Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Medical College of Cornell University
New York, NY, USA

Michael C. Kew, MD

University of Cape Town;
Emeritus Professor and Honorary Professor
University of the Witwatersrand
Johannesburg, South Africa

Akhtar Khan, MD, FACS

Assistant Professor of Surgery
Division of Transplantation
Department of Surgery
Penn State Milton S. Hershey Medical Center
Hershey, PA, USA

Clayton D. Knox, MD, MBA

Vanderbilt University School of Medicine
Nashville, TN, USA

Norihiro Kokudo, MD, PhD

Hepato-Biliary-Pancreatic Surgery Division
Department of Surgery
University of Tokyo
Tokyo, Japan

Laura Kulik, MD

Assistant Professor
Division of Hepatology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL, USA

Wei-Chen Lee, MD

Department of General Surgery
Chang-Gung Memorial Hospital
Chang-Gung University Medical School
Taoyuan, Taiwan

Kuno Lehmann, MD

Department of Surgery
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Mickael Lesurtel, MD, PhD

Department of Surgery
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Steven K. Libutti, MD, FACS

Professor of Surgery, Department of Surgery
Montefiore Medical Center/Albert Einstein
College of Medicine
New York, NY, USA

David C. Linehan, MD

Section of Hepatobiliary, Pancreatic and
Gastrointestinal Surgery
Washington University School of Medicine
Saint Louis, MO, USA

Josep M. Llovet, MD

Associate Professor of Medicine
Liver Cancer Program, Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York, USA;
Professor of Research – ICREA
Barcelona-Clinic-Liver-Cancer (BCLC) Group
Institut d' Investigacions Biomèdiques August Pi
i Sunyer (IDIBAPS)
Centro de Investigaciones Biomédicas en Red
(CIBEREHD)
Liver Unit, Hospital Clínic
Barcelona, Spain

**Chung-Mau Lo, MS, FRCS (Edin),
FRACS, FACS**

Department of Surgery
The University of Hong Kong
Queen Mary Hospital
Hong Kong, China

Masatoshi Makuuchi, MD, PhD

Department of Hepato-Biliary-Pancreatic
Surgery
President Japanese Red Cross Medical Center
Tokyo, Japan

Lucas McCormack, MD

Liver Transplant Program
General Surgery Service
Hospital Aleman
Buenos Aires, Argentina

David Lawson Morris

Professor of Surgery
UNSW Department of Surgery
St George Hospital
Sydney, Australia

Michael A. Morse, MD, MHS

Associate Professor of Medicine
Division of Medical Oncology, GI Oncology
Molecular Therapeutics Program
Duke University Medical Center
Durham, NC, USA

Beat Müllhaupt, MD

Department of Gastroenterology and Hepatology
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Peter Neuhaus, MD

Department of General, Visceral and
Transplantation Surgery
Charité – Universitätsmedizin Berlin
Campus Virchow-Klinikum
Berlin, Germany

Ulf P. Neumann, MD

Department of General, Visceral and
Transplantation Surgery
Charité – Universitätsmedizin Berlin
Campus Virchow-Klinikum
Berlin, Germany

Martin Palavecino, MD

Department of Surgical Oncology
The University of Texas M.D. Anderson Cancer
Center
Houston, TX, USA

Valérie Paradis, MD, PhD

Department of Pathology
Beaujon Hospital
Clichy, France
INSERM U773
Centre de Recherche Bichat Beaujon
Paris, France

Bernhard C. Pestalozzi, MD

Department of Oncology
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Henrik Petrowsky, MD

The Dumont-UCLA Transplant Center
Ronald Reagan Medical Center
David Geffen School of Medicine at UCLA
Los Angeles, CA, USA

Ketsia B. Pierre, MD, MSCI

Department of Surgery
Vanderbilt University Medical Center
Nashville, TN, USA

James F. Pingpank, MD

Associate Professor of Surgery
Department of Surgery
University of Pittsburgh
Pittsburgh, PA, USA

C. Wright Pinson MD, MBA

H. William Scott Professor of Surgery
Deputy Vice-Chancellor for Health Affairs
Vanderbilt University Medical Center
Nashville, TN, USA

Robert J. Porte, MD, PhD

Professor of Surgery
Department of Surgery
Section Hepatobiliary Surgery and Liver
Transplantation
University Medical Center Groningen
University of Groningen
Groningen, The Netherlands

Maria I. Real, MD

Barcelona-Clinic-Liver-Cancer (BCLC) Group
Department of Radiology
Hospital Clínic, University of Barcelona
Centro de Investigaciones Biomédicas en Red
Institut d' Investigacions Biomèdiques August Pi
i Sunyer (IDIBAPS)
Barcelona, Spain

Rakesh Reddy, MBBS

Department of Radiation Oncology
Vanderbilt University
Nashville, TN, USA

Ahsun Riaz, MD

Section of Interventional Radiology
Department of Radiology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL, USA

Xavier Rogiers, MD, PhD

Department of General and Hepatobiliary
Surgery
Transplantation Center
University Medical Center Ghent
Ghent, Belgium

Charles B. Rosen, MD

Professor of Surgery
Division of Transplantation Surgery
Mayo Clinic
Rochester, MN, USA

Riad Salem, MD, MBA

Professor
Interventional Oncology
Section of Interventional Radiology
Department of Radiology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL, USA

Panagiotis Samaras, MD

Department of Oncology
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Daniel Seehofer, MD

Department of General, Visceral and
Transplantation Surgery
Charité – Universitätsmedizin Berlin
Campus Virchow-Klinikum
Berlin, Germany

Contributors

Markus Selzner, MD

Department of Surgery
Multiorgan Transplant Program
Toronto General Hospital
Toronto, Ontario, Canada

Ksenija Slankamenac, MD

Department of Surgery
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Steven M. Strasberg, MD

Pruett Professor of Surgery
Section of Hepatobiliary-Pancreatic Surgery
Washington University in Saint Louis
Saint Louis, MO, USA

Tadatoshi Takayama, MD, PhD

Professor of Surgery
Department of Digestive Surgery
Nihon University School of Medicine
Tokyo, Japan

Sumihito Tamura, MD, PhD

Hepato-Biliary-Pancreatic Surgery Division
Department of Surgery
University of Tokyo
Tokyo, Japan

Tadahiro Uemura, MD,

Assistant Professor of Surgery
Division of Transplantation
Department of Surgery
Penn State Milton S. Hershey Medical Center
Hershey, PA, USA

Jean-Nicolas Vauthey, MD, FACS

Professor of Surgery
Liver Service
Department of Surgical Oncology
The University of Texas M.D. Anderson Cancer
Center
Houston, TX, USA

Luca Viganò, MD

Department of Hepatobiliary and Digestive
Surgery
Ospedale Mauriziano “Umberto I”
Torino, Italy

Augusto Villanueva, MD

Barcelona-Clinic-Liver-Cancer (BCLC) Group
Institut d’ Investigacions Biomèdiques August Pi
i Sunyer (IDIBAPS)
Centro de Investigaciones Biomédicas en Red
(CIBEREHD)
Liver Unit, Hospital Clínic
Barcelona, Spain

Emile E. Voest, MD, PhD

Department of Medical Oncology
University Medical Center
Utrecht, The Netherlands

J. Mathijs Vogten MD, PhD

Department of Surgery
University Medical Center
Utrecht, The Netherlands

René Vonlanthen, MD

Department of Surgery
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Kay Washington, MD, PhD

Department of Pathology
Vanderbilt University Medical Center
Nashville, TN, USA

Achim Weber, MD

Department of Pathology
Institute of Surgical Pathology
Swiss Hepato-Pancreato-Biliary and
Transplantation Center
University Hospital Zurich
Zurich, Switzerland

Dominik Weishaupt, MD

Division of Radiology
Triemli Hospital Zurich
Zurich, Switzerland

Andrew D. Yeoman, MB BCH, MRCP

Institute of Liver Studies
King’s College Hospital
London, UK

Marco P. Zalunardo, MD

Institute of Anesthesiology
University Hospital of Zurich
Zurich, Switzerland

Daria Zorzi, MD

Department of Surgical Oncology
The University of Texas M.D. Anderson Cancer
Center
Houston, TX, USA

Preface

Very few areas in medicine offer as many controversies as the management of liver tumors. Since the publication of the first two editions of the book, in 1999 and 2004 respectively, many novel diagnostic and therapeutic tools have become available. This has brought tremendous excitement and hope for curing previously lethal diseases. However, the recent proliferation of innovative and competitive approaches, often marketed prior to conclusive demonstration of their efficacy, has also brought confusion about which therapeutic modalities to select for a particular case [1].

Today, the success of treating a patient with hepatic malignancy is often linked to the appropriate use of various treatments, combining neoadjuvant and adjuvant modalities with surgery. Thus, the best approach for a patient with an hepatic tumor is achieved by a multidisciplinary team comprising a medical oncologist, hepatologist, hepatic surgeon, radiotherapist, and interventional radiologist. The availability of such specialists in a center *per se* is not enough for success. Of vital importance is the daily interaction of those specialists, which is mandatory in order to provide optimal treatment for each patient presenting with a complex liver malignancy [2].

Since most innovative approaches are still experimental and often technically demanding, patients presenting with hepatic tumors should optimally be managed in centers with a strong commitment to research. Patients often need to travel long distances to reach such centers. Therefore, for adequate long-term management of these patients, it is imperative to establish a close collaboration between specialized centers and local oncologists, as well as other physicians.

To this end, the third edition of *Malignant Liver Tumors* has been extensively revised compared to the two previous editions, including a new format, new associate editors, and 16 new chapters containing guidelines for the treatment of each specific type of malignancy. However, the goal remains similar in providing a comprehensive and critical approach to current and established therapeutic modalities, while critically evaluating promising new avenues. The book was written by a multidisciplinary panel of international

experts, each with extensive experience in this population of patients. Each chapter was reviewed by the Editor, Deputy Editor, two Associate Editors, and at least one external reviewer to achieve comprehensive and balanced coverage of each topic, to minimize redundancy among chapters, and to provide appropriate cross-references. While each chapter can be read separately, the book was written with the intention that the chapters be read sequentially.

The first and second editions received many positive comments published in several surgical, oncologic, and gastrointestinal journals, testifying to the interdisciplinary interest in the field. Besides many eulogistic comments, such as “best book in the area” [3], the most relevant criticism of the second edition appeared in the *New England Journal of Medicine*: “If I were a physician who was consulting this book for advice on how to treat my patient, I would be impressed by how many treatment options my patient had, but I would have no idea how to pick up the best one” [4]. To address this pertinent comment we added an entire new section (Section 5) on “Guidelines for liver tumor treatment,” covering the most common liver malignancies: hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), gallbladder cancer, and colorectal liver metastases. These guidelines were prepared by the Associate Editors, taking into account other guidelines prepared by international or national societies, which should now offer a specific strategy to treat a patient with a specific condition through algorithms.

Each chapter has been updated, often by the original authors. Sixteen new chapters have been added. The book starts with a new chapter (Chapter 1) on the history of liver tumors and their therapies. The next chapter (Chapter 2) is also new, covering the liver anatomy and the consensus terminology for the various types of liver resection. A new emphasis is also given to histologic changes in the liver related to underlying conditions such as steatosis and cirrhosis, as well as neoadjuvant chemotherapies, which are increasingly used in clinical practice (Chapter 4). Three new chapters (Chapters 5–7) cover the epidemiology and the natural history of HCC, CC, and colorectal liver metastases, respectively. Novel developments have occurred in the field of internal radiation therapy of liver tumors, which is

covered in Chapter 12. Strategies for liver resection are newly covered in two separate chapters (Chapters 16 and 17), one for HCC and gallbladder cancer, and another for colorectal metastases. Among the emerging therapies, novel therapies, targeted at specific signaling pathways, appear to be the most promising, and a new chapter has been included which covers relevant signaling pathways in liver tumors (Chapter 31). Finally, a new chapter has been included to cover the economic aspects of the treatment of liver tumors (Chapter 44).

This book also has an important educational purpose, and therefore we include 5–10 questions after each chapter. This will enable the reader to test his or her understanding of the main information in each chapter.

I hope that this third edition of *Malignant Liver Tumors: Current and Emerging Therapies* will prove useful, and will

provide timely information and guidelines for the management of this difficult population of patients.

P.-A.C.

References

- 1 Clavien PA, Petrowsky H, deOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. *N Engl J Med* 2007;**356**:1545–59.
- 2 Clavien PA, Mullhaupt B, Pestalozzi B. Do we need a center approach to treat patients with liver diseases? Forum on Liver Transplantation. *J Hepatol* 2006;**44**:639–42.
- 3 Morris DL. Book review. *Br J Surg* 2000;**87**:1117.
- 4 Di Bisceglie AM. Book review. *N Engl J Med* 2004;**350**:203.



Acknowledgments

Madeleine Meyer, assistant to the Editor, deserves special thanks for her enthusiasm and tireless work to get each initial and revised chapter in on time. A hearty thanks goes to all authors who often served as reviewers of other chapters, and in particular to the Associate Editors, Jacques

Belghiti, Ravi Chari, Chung-Mau Lo, Josep Llovet, Michael Morse, Tadatoshi Takayama, and Jean-Nicolas Vauthey, as well as the Deputy Editor, Stefan Breitenstein, who despite their busy schedules have dedicated a large amount of their time to the success of this book.

Abbreviations

5-FU	5-fluorouracil	ERCP	endoscopic retrograde cholangiopancreatography
AFLD	alcoholic fatty liver disease	ERK	extracellular signal-regulated kinase
AFP	alpha-fetoprotein	FDG	fluoro-2-deoxy-D-glucose
AFU	alpha-L-fucosidase	FLR	future liver remnant
AIDS	acquired immunodeficiency syndrome	FNH	focal nodular hyperplasia
Akt	protein kinase B	FSE	fast spin echo
APAF-1	apoptosis protease activating factor	FUDR	floxuridine
ASH	alcoholic steatohepatitis	GRE	gradient recalled echo
ATP	adenosine triphosphate	GSK-3 β	glycogen synthase kinase 3 beta
BMI	body mass index	GTV	gross tumor volume
BSC	best supportive care	H&E	hematoxylin and eosin
CAG	chronic atrophic gastritis	HAC	hepatic artery chemotherapy
CASH	chemotherapy-associated steatohepatitis	HAI	hepatic arterial infusion
CBA	cost-benefit analysis	HBV	hepatitis B virus
CC	cholangiocarcinoma	HCC	hepatocellular carcinoma
CEA	cost-effective analysis	HCG	human chorionic gonadotropin
CEUS	contrast-enhanced ultrasound	HCV	hepatitis C virus
CGH	comparative genomic hybridization	HEHE	hepatic epithelioid hemangioendothelioma
CK	cytokeratin	HNPPC	hereditary nonpolyposis colorectal cancer
CLM	colorectal liver metastasis	HIV	human immunodeficiency virus
CRC	colorectal cancer	HPB	hepato-pancreatico-biliary
CSI	chemical shift imaging	HSC	hepatic stellate cell
CT	computed tomography	IAP	inhibitor of apoptosis protein
CTAP	computed tomography during arterial portography	ICC	intrahepatic cholangiocarcinoma
CTHA	computed tomography during hepatic arteriography	ICER	incremental cost-effectiveness ratio
CTNNB1	catenin (cadherin-associated protein), beta	ICG	indocyanine green
CTV	clinical target volume	IGF	insulin-like growth factor
CUA	cost-utility analysis CEA, carcinoembryonic antigen	IHP	isolated hepatic perfusion
CUSA	cavitron ultrasonic surgical aspiration	IL	interleukin
CyA	cyclosporin A	IMTP	intensity modulated radiation therapy
DFS	disease-free survival	IOUS	intraoperative ultrasound
DRG	diagnosis-related group	ITV	internal target volume
ECC	extrahepatic cholangiocarcinoma	IVC	inferior vena cava
ECM	extracellular matrix	LDLT	living donor liver transplantation
EGF	epidermal growth factor	LMET	liver metastases from endocrine tumor
EGFR	epidermal growth factor receptor	LOH	loss of heterozygosity
ERC	endoscopic retrograde cholangiography	LSF	lung shunt function
		MAPK	mitogen-activated protein kinase
		MDCT	multidetector-row computed tomography

MEK	mitogen-activated protein kinase	PTEN	phosphatase and tensin homolog
MELD	model for end-stage liver disease	PTV	planning target volume
MEN	multiple endocrine neoplasia	PVE	portal vein embolization
MIP	maximum intensity projections	PVT	portal vein thrombosis
MMAC	mutated in multiple advanced cancer	QALY	quality adjusted life year
MMF	mycophenolate mofetil	RAD	radiation absorbed dose
MNET	metastatic neuroendocrine tumor	RECIST	response evaluation criteria in solid tumor
MRC	magnetic resonance cholangiography	RFA	radiofrequency ablation
MRCP	magnetic resonance cholangiopancreatography	RILD	radiation-induced liver disease
MRI	magnetic resonance imaging	RLN	regional lymph node
mTOR	mammalian target of rapamycin	RTK	receptor tyrosine kinase
MWA	microwave ablation	SBRT	stereotactic body radiotherapy
NAFLD	nonalcoholic fatty liver disease	SEER	surveillance epidemiology and end results
NASH	nonalcoholic steatohepatitis	SIRT	selective internal radiation therapy
NCNEM	noncolorectal nonendocrine metastases	SMA	superior mesenteric artery
NET	neuroendocrine tumor	SNP	single nucleotide polymorphism
NIH	National Institutes of Health	STAT	signal transducers and activators of transcription
NO	nitric oxide	TACE	transarterial chemoembolization
NSF	nephrogenic systemic sclerosis	TAE	transarterial embolization
OLT	orthotopic liver transplantation	TART	transarterial radionuclide therapy
PAAI	percutaneous acetic acid injection	TGF	transforming growth factor
PAS	periodic acid–Schiff	TKR	tyrosine kinase receptor
PEI	percutaneous ethanol injection	TLV	total liver volume
PET	positron emission tomography	TNF	tumor necrosis factor
PFS	progression free survival	TNM	tumor/node/metastasis
PHoT	percutaneous hot saline therapy	TPP	time to progression
PHP	percutaneous hepatic perfusion	UPA	urokinase-type plasminogen activator
PI3K	phosphoinositid-3-kinase	VEGF	vascular endothelial growth factor
PKC	protein kinase C	VOD	veno-occlusive disease
PSC	primary sclerosing cholangitis	ZES	Zollinger–Ellison syndrome
PTC	percutaneous transhepatic cholangiogram		

Contents

Contributors, vii

Preface, xi

Acknowledgments, xiii

Abbreviations, xiv

Section 1 Introduction, 1

- 1 From Promethean to Modern Times, 3
Kuno Lehmann, Stefan Breitenstein, and Pierre-Alain Clavien

- 2 Hepatic Anatomy and Terminology, 11
Steven M. Strasberg

Section 2 Epidemiology and Diagnosis, 27

Introduction, 29
Chung-Mau Lo

- 3 Histology and Pathology of Normal and Diseased Liver, 30
Valérie Paradis and Achim Weber
- 4 Pathology of Primary and Secondary Malignant Liver Tumors, 40
Kay Washington
- 5 Epidemiology, Etiology, and Natural History of Hepatocellular Carcinoma, 52
Wei-Chen Lee and Miin-Fu Chen
- 6 Epidemiology, Etiology, and Natural History of Cholangiocarcinoma, 56
Peter Neuhaus, Ulf P. Neumann, and Daniel Seehofer
- 7 Epidemiology, Etiology, and Natural History of Colorectal Liver Metastases, 64
Robert J. Porte
- 8 Tumor Markers in Primary and Secondary Liver Tumors, 69
Ketsia B. Pierre and Ravi S. Chari

- 9 Modalities for Imaging Liver Tumors, 76
Dominik Weishaupt and Thomas F. Hany

Section 3 Systemic and Regional Therapies, 103

Introduction, 105
Ravi S. Chari

- 10 Systemic Treatment of Hepatobiliary Tumors, 107
Panagiotis Samaras, Michael A. Morse, and Bernhard C. Pestalozzi
- 11 External Beam Radiation Therapy for Liver Tumors, 122
Rakesh Reddy and A. Bapsi Chakravarthy
- 12 Internal Radiation Therapy for Liver Tumors, 131
Ahsun Riaz, Laura Kulik, Michael Abecassis, and Riad Salem
- 13 Transarterial Embolization for Patients with Hepatocellular Carcinoma, 139
Jordi Bruix, Carmen Ayuso, and Maria I. Real
- 14 Selective Continuous Intra-arterial Chemotherapy for Liver Tumors, 151
Fidel D. Huitzil-Melendez, Stefan Breitenstein, and Nancy Kemeny
- 15 Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion, 164
Charles K. Heller, III, James F. Pingpank, and Steven K. Libutti

Section 4 Resection, Ablation or Transplantation for Liver Tumors, 173

Introduction, 175
Jean-Nicolas Vauthey and Tadatoshi Takayama

- 16 Liver Resection of Primary Tumors: Hepatocellular Carcinoma, Cholangiocarcinoma, and Gallbladder Cancer, 177
Tadatoshi Takayama and Masatoshi Makuuchi

- 17 Liver Resection of Colorectal Liver Metastases, 192
Daria Zorzi, Yun Shin Chun, and Jean-Nicolas Vauthey
- 18 Laparoscopic Liver Resection, 203
Luca Viganò and Daniel Cherqui
- 19 Repeat Resection for Liver Tumors, 216
Mickael Lesurtel and Henrik Petrowsky
- 20 Cryoablation of Liver Tumors, 227
Sivakumar Gananadha and David L. Morris
- 21 Thermal Ablation of Liver Tumors by Radiofrequency, Microwave, and Laser Therapy, 244
M. B. Majella Doyle and David C. Linehan
- 22 Ethanol and Other Percutaneous Injection Modalities in the Treatment of Liver Tumors, 266
Michael A. Heneghan and Andrew D. Yeoman
- 23 Transplantation for Liver Tumors, 281
François Durand, Claire Francoz, and Jacques Belghiti
- 24 Preventing Recurrence of Hepatocellular Carcinoma after Curative Resection, 296
Stefan Breitenstein, Dimitris Dimitroulis, and Beat Müllhaupt

Section 5 Guidelines for Liver Tumor Treatment, 305

- Introduction, 307
Stefan Breitenstein and Pierre-Alain Clavien
- 25 Strategies for Safer Liver Surgery, 308
Philipp Dutkowski, Olivier de Rougemont, and Pierre-Alain Clavien
- 26 Hepatocellular Carcinoma, 317
Tadatoshi Takayama
- 27 Cholangiocarcinoma, 324
Jacques Belghiti and Charles B. Rosen
- 28 Gallbladder Cancer, 333
Juan Hepp and Chung-Mau Lo
- 29 Colorectal Liver Metastases, 342
Phuong L. Doan, Jean-Nicolas Vauthey, Martin Palavecino, and Michael A. Morse

Section 6 Emerging Therapies, 347

- Introduction, 349
Michael A. Morse and Josep M. Llovet
- 30 Viral-Based Therapies for Primary and Secondary Liver Cancer, 352
Menghua Dai, Lorena Gonzalez, and Yuman Fong

- 31 Signaling Pathways and Rationale for Molecular Therapies in Hepatocellular Carcinoma, 368
Augusto Villanueva, Clara Alsinet, and Josep M. Llovet
- 32 Novel Therapies Targeted at Signal Transduction in Liver Tumors, 382
Fidel D. Huitzil-Melendez, Ghassan K. Abou-Alfa, and Michael A. Morse
- 33 Induction of Apoptosis in Liver Tumors, 393
Markus Selzner and Pierre-Alain Clavien
- 34 Antiangiogenic Agents for Liver Tumors, 400
Mathijs Vogten, Emile E. Voest, and Inne H.M. Borel Rinkes
- 35 Integrative Oncology: Alternative and Complementary Treatments, 414
Barrie R. Cassileth and Jyothirmai Gubili

Section 7 Special Tumors, Population, and Special Considerations, 421

- Introduction, 423
Stefan Breitenstein and Pierre-Alain Clavien
- 36 Liver Metastases from Endocrine Tumors, 424
Clayton D. Knox and C. Wright Pinson
- 37 Uncommon Primary and Metastatic Liver Tumors, 439
Stefan Breitenstein, Ashraf Mohammad El-Badry, and Pierre-Alain Clavien
- 38 Liver Tumors in Special Populations, 454
Tadahiro Uemura, Akhtar Khan, and Zakiyah Kadry
- 39 Malignant Liver Tumors in Children, 475
Xavier Rogiers and Ruth De Bruyne
- 40 Liver Tumors in Asia, 487
Norihiro Kokudo, Sumihito Tamura, and Masatoshi Makuuchi
- 41 Liver Tumors in South America, 500
Lucas McCormack and Eduardo de Santibañes
- 42 Liver Tumors in Africa, 509
Michael C. Kew
- 43 Anesthetic Management of Liver Surgery, 519
Marco P. Zalunardo
- 44 Qualitative and Economic Aspects of Liver Surgery, 531
René Vonlanthen, Ksenija Slankamenac, and Christian Ernst

Index, 539

1

Introduction

From Promethean to Modern Times

Kuno Lehmann, Stefan Breitenstein, and Pierre-Alain Clavien

Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland

From myths to mysteries

In the dark ages of our ancestors, liver surgery was inexistent and the organ was a source for myths, legends, and spirituality. During the Babylonian era (~3000–1500 BC), the liver was thought to bear the soul. Priests used hepatoscopy in animal livers as a tool for divine connection, predicting the future. Clay models of sheep livers, probably used for teaching or divination, still exist from this period.

The famous legend of Prometheus was written by Hesiod (750–700 BC), recounting very ancient times (Figure 1.1). Prometheus stole fire from Zeus, the godfather of ancient Greece, and gave it to mankind. For this infringement, the angry Zeus chained him to a rock and sent an eagle to devour his liver. Prometheus was captured in eternal pain. The liver regenerated and gained its normal size overnight, and the hungry eagle returned daily to its victim. Over 2000 years later, the amazing regenerative capacity of the liver is no longer a mystical tale, but the basis for current hepatobiliary surgery and a promising topic of surgical research [1].

Probably the first anatomist to describe the liver was the Alexandrian Herophilus (330–280 BC). Although his written work has not survived, another famous scientist cited him. This was the Greek Galen (130–200 AD), who dominated medical literature for the following centuries. He made accurate descriptions of the lobar anatomy and the vasculature, interpreting the liver as the source of blood. In contrast to his empirical anatomic insights, he propagated a humoral basis of medicine. Originating from the theories of Hippocrates (460–380 BC), diseases were based on an imbalance of the four humors: black and yellow bile, blood and phlegm. However, in the following years and centuries of the Middle Ages, theories became traditions and knowledge moved forward very little. Brilliant exceptions were Leonardo da Vinci's drawings of the extra- and intra-hepatic portal and venous vessels.

In 1640, Johannis Walaeus, from Leiden, Netherlands, reported a common tunic, surrounding the branches of the choledochal duct, the celiac artery, and the portal vein. In 1654, Francis Glisson, from Cambridge, England removed the liver parenchyma by cooking the organ in hot water and explored the hepatic blood flow with colored milk [2]. He discussed the intrahepatic anatomy and topography of the vasculature (Figure 1.2). The growing knowledge of liver anatomy was one of the substantial preconditions for the development of liver surgery. However, this was still far from realization, and the liver remained a fragile bleeding mystery. We would like to refer to the comprehensive overview by McClusky *et al* for the fruitful interaction between anatomists and pioneers of liver surgery [3].

Of inquisitive anatomists and courageous surgeons

In 1842, Crawford W. Long used ether as a surgical anesthetic for the first time in the United States. This was a fundamental step in the development of abdominal surgery. In 1867, Joseph Lister from Glasgow, Scotland, introduced antiseptic techniques against bacterial infections after Louis Pasteur, from Paris, France, had discovered the dangers of bacteria.

Before this period, only anecdotal records exist of descriptions about the removal of protruding liver tissue after trauma. Among these surgeons were Ambroise Paré from Paris, France, J.C. Massie from the United States, Victor von Bruns from Germany, and many others. However, liver trauma at this time was generally managed without operation. It took many years before any courageous surgeon was successful in the first attempt of a planned liver resection.

Carl Langenbuch from Berlin, Germany (Figure 1.3), who was among those to perform the first cholecystectomy, reported the first elective and successful hepatic resection in 1888 [4]. William W. Keen from Philadelphia performed the first liver resection in the United States in 1891. He used the "finger-fracture" technique to divide the liver parenchyma. By 1899, the first case series were being reported in the